See more : Otsuka Corporation (OSUKF) Income Statement Analysis – Financial Results
Complete financial analysis of United Health Products, Inc. (UEEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of United Health Products, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Kung Sing Engineering Corporation (5521.TW) Income Statement Analysis – Financial Results
- Lewinsky-Ofer Ltd. (LEOF.TA) Income Statement Analysis – Financial Results
- Humm Group Limited (HUM.AX) Income Statement Analysis – Financial Results
- Gol Linhas Aéreas Inteligentes S.A. (GOLLQ) Income Statement Analysis – Financial Results
- Zahav Inc. (ZAHA) Income Statement Analysis – Financial Results
United Health Products, Inc. (UEEC)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
About United Health Products, Inc.
United Health Products, Inc. develops, manufactures, and markets hemostatic gauze products for the healthcare and wound care sectors in the United States. The company offers HemoStyp hemostatic gauze products to absorb exudate/drainage from superficial wounds, as well as helps in controlling bleeding. It serves hospitals and surgery centers, clinics and physicians, military medical care providers, hemodialysis centers, assisted living and nursing homes, and veterinary hospitals; and EMS, fire departments, and other first responders, as well as dental, oral, and maxillofacial surgery offices. The company was formerly known as United EcoEnergy Corp. and changed its name to United Health Products, Inc. in September 2010. United Health Products, Inc. was incorporated in 1997 and is headquartered in Henderson, Nevada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 37.50K | 59.00 | 643.00 | 4.93K | 45.86K | 645.65K | 242.01K | 53.27K | 162.68K | 3.06K | 0.00 | 0.00 | 69.07K | 23.90K | 8.19K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.86K | 18.64K | 25.00 | 195.00 | 1.32K | 96.70K | 67.02K | 117.93K | 27.51K | 82.96K | 0.00 | 0.00 | 0.00 | 56.45K | 16.64K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.86K | 18.86K | 34.00 | 448.00 | 3.61K | -50.84K | 578.64K | 124.08K | 25.75K | 79.71K | 3.06K | 0.00 | 0.00 | 12.62K | 7.26K | 8.19K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 50.28% | 57.63% | 69.67% | 73.29% | -110.85% | 89.62% | 51.27% | 48.35% | 49.00% | 100.00% | 0.00% | 0.00% | 18.28% | 30.38% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 598.81K | 624.56K | 237.46K | 245.22K | 666.39K | 76.95K | 19.94K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.22M | 107.02K | 0.00 | 0.00 | 487.06K | 284.88K | 228.27K | 191.16K | 15.50K |
| Selling & Marketing | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.82M | 2.20M | 29.56M | 14.60M | 5.43M | 2.25M | 1.30M | 641.55K | 2.61M | 2.12M | 1.22M | 107.02K | 1.22M | 2.55M | 487.06K | 284.88K | 228.27K | 191.16K | 15.50K |
| Other Expenses | 0.00 | 1.40M | 304.27K | 0.00 | 0.00 | 3.94K | 0.00 | 0.00 | 0.00 | 50.00K | 259.04K | 100.00K | 100.00K | 100.00K | 50.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.43M | 2.82M | 29.80M | 14.85M | 6.10M | 2.33M | 1.30M | 641.55K | 2.61M | 2.17M | 1.32M | 207.02K | 1.32M | 2.65M | 537.06K | 284.88K | 228.27K | 191.16K | 15.50K |
| Cost & Expenses | 2.43M | 2.84M | 29.80M | 14.85M | 6.10M | 2.42M | 1.36M | 759.48K | 2.64M | 2.25M | 1.32M | 207.02K | 1.32M | 2.70M | 553.70K | 284.88K | 228.27K | 191.16K | 15.50K |
| Interest Income | 0.00 | 78.85K | 618.25K | 546.23K | 508.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 74.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 78.85K | 618.25K | 546.23K | 508.18K | 0.00 | 39.48K | 18.26K | 9.15K | 52.15K | 68.70K | 0.00 | -270.95K | 81.13K | 81.30K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.05K | 4.05K | 29.80M | 14.85M | 6.09M | 1.90M | 1.01M | 517.48K | 50.00K | 50.00K | 100.00K | 100.00K | 100.00K | 100.00K | 50.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -2.50M | -1.60M | -748.55K | -862.75K | -6.09M | -5.40M | -534.67K | -517.48K | -2.58M | -2.04M | -1.22M | -107.02K | -1.22M | -2.53M | -796.32K | -276.69K | -228.27K | -191.16K | -15.50K |
| EBITDA Ratio | 0.00% | -3,720.02% | -49,993,833.90% | -2,309,276.98% | -123,688.09% | -5,175.60% | -82.81% | -213.83% | -4,848.71% | -1,255.36% | -39,761.67% | 0.00% | 0.00% | -3,929.97% | -3,171.08% | -3,378.38% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.43M | -2.80M | -29.80M | -14.85M | -6.09M | -2.38M | -719.32K | -517.48K | -2.58M | -2.09M | -1.32M | -207.02K | -1.32M | -2.63M | -529.79K | -276.69K | -228.27K | -191.16K | -15.50K |
| Operating Income Ratio | 0.00% | -7,472.10% | -50,509,550.85% | -2,309,276.98% | -123,688.09% | -5,184.18% | -111.41% | -213.83% | -4,848.71% | -1,286.10% | -43,029.64% | 0.00% | 0.00% | -3,814.15% | -2,216.43% | -3,378.38% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -196.73K | 1.11M | -748.55K | -862.75K | -508.18K | -3.51M | -215.65K | -18.26K | -9.15K | -52.15K | 190.34K | -74.40K | -270.95K | -261.13K | -380.21K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -2.62M | -1.69M | -30.55M | -15.71M | -6.60M | -6.01M | -934.97K | -535.74K | -2.59M | -2.14M | -1.13M | -281.41K | -1.59M | -2.90M | -910.01K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | -4,500.00% | -51,778,276.27% | -2,443,452.57% | -134,002.33% | -13,096.10% | -144.81% | -221.37% | -4,865.88% | -1,318.15% | -36,809.35% | 0.00% | 0.00% | -4,192.21% | -3,807.08% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.11K | 618.25K | 546.23K | 508.18K | 3.63M | 31.00K | -517.48K | -50.00K | 0.00 | 68.70K | 0.00 | 0.00 | -98.87K | -196.89K | 276.69K | 228.27K | 191.16K | 15.50K |
| Net Income | -2.62M | -1.69M | -31.17M | -16.26M | -7.11M | -6.01M | -934.97K | -535.74K | -2.59M | -2.14M | -1.13M | -281.41K | -1.59M | -2.90M | -910.01K | -276.69K | -228.27K | -191.16K | -15.50K |
| Net Income Ratio | 0.00% | -4,497.03% | -52,826,159.32% | -2,528,402.49% | -144,316.58% | -13,096.10% | -144.81% | -221.37% | -4,865.88% | -1,318.15% | -36,809.35% | 0.00% | 0.00% | -4,192.21% | -3,807.08% | -3,378.38% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.01 | -0.14 | -0.09 | -0.04 | -0.03 | -0.01 | 0.00 | -0.02 | -0.02 | -0.01 | 0.00 | -0.02 | -0.06 | -0.02 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.14 | -0.09 | -0.04 | -0.03 | -0.01 | 0.00 | -0.02 | -0.02 | -0.01 | 0.00 | -0.02 | -0.06 | -0.02 | -0.01 | -0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 239.09M | 229.72M | 225.74M | 183.76M | 175.88M | 172.12M | 155.83M | 152.10M | 138.68M | 102.95M | 94.40M | 83.37M | 80.85M | 50.96M | 39.36M | 33.66M | 28.78M | 28.62M | 52.09M |
| Weighted Avg Shares Out (Dil) | 239.08M | 229.72M | 225.74M | 183.76M | 175.88M | 172.12M | 155.83M | 152.10M | 138.68M | 102.95M | 94.40M | 83.37M | 80.85M | 50.96M | 39.36M | 33.66M | 41.78M | 41.73M | 52.09M |
United Health Products Provides Update on Clinical Study Process
MT. LAUREL, N.J., Dec. 02, 2024 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company's planned clinical study.
United Health Products Submits Response Letter to FDA
MT. LAUREL, NJ, Aug. 19, 2024 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company's FDA Premarket Approval (PMA) application process.
United Health Products Submits Full FDA PMA Application
MOUNT LAUREL, NJ, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company's FDA Premarket Approval application process.
United Health Products Reports on FDA Application Status
MESQUITE, NV, Jan. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – United Health Products (UEEC) reports today on the receipt and review of final reports on product sterilization and stability testing for its hemostatic gauze. As previously disclosed, UHP has been...
The Medicare Gold Rush Is Slowing Down
UnitedHealth's disappointing outlook and the Humana sale talks intensify concerns that the Medicare Advantage business isn't what it once was.
United Health Products Reports on FDA Application Status
MESQUITE, NV, Oct. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company's FDA Premarket Approval application process.
United Health Products Reports on Product Testing for FDA Application
MESQUITE, NV, Aug. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company's FDA Premarket Approval application process.
Dow Stocks To Trade In June
This long/short strategy is producing profitable results. Here is what to do now.
Dow Stocks To Trade In December
December is likely to bring higher prices. Here are long and short recommendations.
Stocks To Trade In December
Here are the long-short recommendations for this month.
Source: https://incomestatements.info
Category: Stock Reports